Skip to main content

Top Bar Menu

Go to LUNGevity.org › Sign Up For Emails

  • Non-Small Cell Lung Cancer
    • NSCLC
    • ALK
    • EGFR
    • KRAS
    • Rare Mutations
  • Small Cell Lung Cancer
  • Resources
    • Clinical Trials
    • Find a Cancer Center
    • Resource Library
    • Podcast

Go to LUNGevity.org › Sign Up For Emails

Patient Gateways

Top Bar Menu

Go to LUNGevity.org › Sign Up For Emails

  • Non-Small Cell Lung Cancer
    • NSCLC
    • ALK
    • EGFR
    • KRAS
    • Rare Mutations
  • Small Cell Lung Cancer
  • Resources
    • Clinical Trials
    • Find a Cancer Center
    • Resource Library
    • Podcast

Main navigation

Close Menu
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials

You are about to leave the Patient Gateway

You’re one click away from learning about one of our most valued sponsors. Read about how they’re making a difference in patients’ lives.

ProceedCancel

Patient Gateway

RSS Feed

  • NSCLC Feed
  • ALK Feed
  • EGFR Feed
  • KRAS Feed
  • Rare Mutations Feed
  • SCLC Feed
Imagene AI and Mindpeak Collaborate to Bring AI-Powered NSCLC Biomarker Profiling into Digital Pathology Workflows

Cofactor Genomics Publishes OncoPrism-NSCLC Clinical Validation, Advancing Lung Cancer Immunotherapy Diagnostics Beyond PD-L1

High-throughput fabrication of HAMA/matrigel core-shell hydrogel microspheres by droplet microfluidics for in vitro NSCLC model

把握术后早期干预窗口,奥希替尼辅助治疗助力 EGFR 突变 NSCLC 实现长期生存_腾讯新闻

Simultaneous occurrence of HER2 mutation and PD-L1 high expression in EGFR-mutant NSCLC: a case report

Sample Adequacy PD-L1 and NGS in NSCLC: Shape-Sensing Robotic Assisted Bronchoscopy Versus CT Guided Lung Biopsy

AENEAS2: Aumolertinib Plus Chemotherapy Extends PFS in EGFR-Mutant Advanced NSCLC

Cancer therapy-related cardiovascular toxicity observed during third-generation EGFR-TKI-based treatment in EGFR-mutant NSCLC: a retrospective cohort study

Unveiling the heterogeneity: PD-L1 expression and metabolic activity in primary vs. metastatic NSCLC, a retrospective single-center analysis

DECIDE-MET Trial: Targeted Therapy or Immunotherapy First in METex14 NSCLC?

SHARE

The Patient Gateways are a project of LUNGevity Foundation, an organization transforming how people are diagnosed and live with lung cancer. Learn more here.

Privacy policy | Contact us

 

This website is not intended to, and does not, provide medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

 

Copyright © 2026 LUNGevity Foundation. All rights reserved.